Suppr超能文献

选择性5-羟色胺再摄取抑制剂所致的5-羟色胺综合征:综述

Selective serotonin reuptake inhibitor-induced serotonin syndrome: review.

作者信息

Lane R, Baldwin D

机构信息

Pfizer Incorporated, New York, New York 10017-5755, USA.

出版信息

J Clin Psychopharmacol. 1997 Jun;17(3):208-21. doi: 10.1097/00004714-199706000-00012.

Abstract

The selective pharmacology of the selective serotonin reuptake inhibitors (SSRIs) results in a lower potential for pharmacodynamic drug interactions relative to other antidepressants such as the tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). However, the SSRIs have been implicated in the development of the serotonin syndrome--a potentially life-threatening complication of treatment with psychotropic drugs. The syndrome is produced most often by the concurrent use of two or more drugs that enhance central nervous system serotonin activity and often goes unrecognized because of the varied and nonspecific nature of its clinical features. The serotonin syndrome is characterized by alterations in cognition (disorientation, confusion), behavior (agitation, restlessness), autonomic nervous system function (fever, shivering, diaphoresis, diarrhea), and neuromuscular (ataxia, hyperreflexia, myoclonus) activity. The difference between this syndrome and the occurrence of adverse effects caused by serotonin reuptake inhibitors alone is the clustering of the signs and symptoms, their severity, and their duration. There are important pharmacokinetic interactions between SSRIs and other serotonergic drugs due principally to their effects on the cytochrome P450(CYP) isoenzymes, the potential for which varies widely amongst the SSRI group, which may increase the likelihood of a pharmacodynamic interaction. The exceptionally long washout period required after fluoxetine discontinuation may cause additional problems and/or inconvenience. Patients with serotonin syndrome usually respond to discontinuation of drug therapy and supportive care alone, but they may also require treatment with antiserotonergic agent such as cyproheptadine, methysergide, and/or propranolol. To reduce the occurrence, morbidity, and mortality of the serotonin syndrome, it must be both prevented by prudent pharmacotherapy and given prompt recognition when it is present.

摘要

与其他抗抑郁药(如三环类抗抑郁药和单胺氧化酶抑制剂)相比,选择性5-羟色胺再摄取抑制剂(SSRI)的选择性药理作用使其发生药效学药物相互作用的可能性更低。然而,SSRI与5-羟色胺综合征的发生有关——这是一种使用精神药物治疗时可能危及生命的并发症。该综合征最常由同时使用两种或更多种增强中枢神经系统5-羟色胺活性的药物引起,并且由于其临床特征多样且不具特异性,常常未被识别。5-羟色胺综合征的特征包括认知改变(定向障碍、意识模糊)、行为改变(激动、坐立不安)、自主神经系统功能改变(发热、寒战、出汗、腹泻)以及神经肌肉活动改变(共济失调、反射亢进、肌阵挛)。该综合征与单独由5-羟色胺再摄取抑制剂引起的不良反应的区别在于症状和体征的聚集、其严重程度及持续时间。SSRI与其他5-羟色胺能药物之间存在重要的药代动力学相互作用,主要是因为它们对细胞色素P450(CYP)同工酶有影响,这种可能性在SSRI组中差异很大,这可能会增加药效学相互作用的可能性。停用氟西汀后所需的异常长的洗脱期可能会引起更多问题和/或不便。5-羟色胺综合征患者通常仅通过停药和支持性治疗即可恢复,但他们可能还需要用抗5-羟色胺能药物进行治疗,如赛庚啶、甲基麦角新碱和/或普萘洛尔。为了减少5-羟色胺综合征的发生、发病率和死亡率,必须通过谨慎的药物治疗来预防,并且在出现时要迅速识别。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验